Bread for celiac vaccine

ImmusanT Inc. is working on a peptide-based therapeutic vaccine designed to address the underlying problem in celiac disease, and received $20 million in series A money last week to pursue proof-of-concept data.

"We believe this immune-based therapy has transformational potential for celiac disease because it is the first product in development where people can continue to live a normal lifestyle and not worry about maintaining a gluten-free diet," said Sundar Kodiyalam of Vatera Healthcare Partners, the sole investor in the round...